07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Oral vaccine and adjuvant data

ANTX announced that preliminary findings from safety testing of its Campylobacter vaccine in healthy volunteers show increased immunogenic response when the oral mucosal adjuvant was added. A more complete analysis of the placebo-controlled, double-blind trial...
07:00 , Jul 11, 2005 |  BioCentury  |  Strategy

Immunizing against risk

Although Emergent BioSolutions Inc. has been a major beneficiary of U.S. government demand for biodefense products, the company decided it needed to broaden both its future investor appeal and its commercial vaccines portfolio. It didn't...
07:00 , Jun 9, 2003 |  BC Week In Review  |  Company News

Antex, BioPort deal

BioPort purchased ANX's assets for $3.4 million. BioPort had planned to acquire ANX, but the acquisition was called off and BioPort instead purchased the assets (see BioCentury, March 31). Antex Biologics Inc. (ANX), Gaithersburg, Md....
08:00 , Mar 31, 2003 |  BC Week In Review  |  Company News

Antex, BioPort deal

ANX said that BioPort terminated its proposed acquisition of ANX (see BioCentury, March 24). As a result, ANX filed for reorganization under Chapter 11 of the U.S. Bankruptcy Code. Antex Biologics Inc. (ANX), Gaithersburg, Md....
08:00 , Mar 24, 2003 |  BC Week In Review  |  Company News

Antex, BioPort deal

Anthrax vaccine manufacturer BioPort will acquire ANX for $3 million in cash or $3.6 million in cash and notes. ANX develops products to prevent and treat infections and related diseases. Additionally, BioPort will fund ANX's...
08:00 , Mar 17, 2003 |  BC Extra  |  Company News

BioPort acquiring Antex

Anthrax vaccine manufacturer BioPort (Lansing, Mich.) will acquire ANX for $3 million in cash or $3.6 million in cash and notes. ANX develops products to prevent and treat infections and related diseases. Additionally, BioPort will...
08:00 , Mar 3, 2003 |  BioCentury  |  Finance

Ebb & Flow

The European biotech sector has trended down since the beginning of the year, despite a short runup in the first three weeks. In Continental Europe, the BioCentury Europe index is now down 10% from Dec....
08:00 , Feb 27, 2003 |  BC Extra  |  Financial News

Antex withdraws offering, may sell assets

ANX withdrew its follow-on offering, and said it may be forced to merge or sell the company if it cannot raise additional capital. ANX, which is developing vaccines and immunotherapeutics for bacterial infections, posted an...
08:00 , Feb 10, 2003 |  BC Week In Review  |  Clinical News

Tracvax: Phase I

Antex submitted an IND to the FDA to begin an open-label Phase I trial of Tracvax. Antex Biologics Inc. (ANX), Gaithersburg, Md.   Product: Tracvax   Business: Infectious diseases   Molecular target: NA   Description:...
08:00 , Feb 3, 2003 |  BioCentury  |  Finance

Bio-warfare plays

Bio-warfare plays Company Approach 1/31 cls Wk chg % chg Mkt cap chg ($M) 1/31 mkt cap ($M) Int'l BioChemical (IBCL) Antimicrobial $0.15 $0.13 625% $10.0 $11.6 Antex (ANX) Vaccine $0.57 $0.08 16% $1.0 $7.1...